Valuation : ALLOVIRPAR

Market Cap 49.21M 42.28M 39.84M 36.32M 67.92M 4.68B 68.17M 471M 182M 2.39B 185M 181M 7.55B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -59.36M -55.93M -50.98M -95.33M -6.57B -95.69M -662M -256M -3.35B -259M -254M -10.6B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-4.41%
Current month-64.63%
Current year-64.63%
3 years 3.45
Extreme 3.45
67.39
5 years 3.45
Extreme 3.45
607.43
10 years 3.45
Extreme 3.45
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -164M -154M -141M -263M -18.11B -264M -1.82B -705M -9.23B -715M -699M -29.21B -58.77M -50.5M -47.58M -43.37M -81.11M -5.59B -81.41M -563M -218M -2.85B -221M -216M -9.01B
Net Debt -157M -134M -127M -116M -216M -14.89B -217M -1.5B -580M -7.59B -587M -575M -24.01B -118M -102M -95.77M -87.29M -163M -11.25B -164M -1.13B -438M -5.74B -444M -434M -18.14B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
26-09-09 US$3.470 -4.41%
26-09-08 US$3.630 -6.92%
26-09-04 US$3.900 -1.02%
26-09-03 US$3.940 +1.03%
26-09-02 US$3.900 -0.51%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!